Generalized pustular psoriasis
Conditions
Interventions
None listed
Sponsors
Nippon Boehringer Ingelheim, Inc
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who have been diagnosed with GPP based on the 2006 JDA criteria within 10 years of the date of each ERC approval 2)Patients who had at least 6 months or more continuous observation at the study sites within 10 years of the date of each ERC approval 3)Patients who have obtained written consent for this study from the patient or proxy However, patients who are unlikely to visit the hospital due to death or transfer to another hospital may only participate in the retrospective study under an opt-out
Exclusion criteria
Exclusion criteria: 1)Patients participating in clinical trials for medical devices or drugs at the time of enrolment in this study 2)Patients who have participated in clinical trial for medical device or drugs prior to enrolment in this study. However, if the products are in approved dosage and administration, it does not meet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Frequency of acute GPP flares 2) Severity of acute GPP flares | — |
Countries
Japan
Contacts
Public ContactHayato Konishi
MEBIX INC. CLINICAL OPERATIONS
Outcome results
None listed